Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
First Claim
Patent Images
1. A method for increasing blood flow in a mammal comprising administering a stable liquid formulation to said mammal, wherein said stable liquid formulation consists essentially of:
- (a) a low dose of an alpha adrenergic receptor antagonist, a buffer for maintaining pH, an aqueous solvent, a metal chelator, optionally a tonicity modifier, optionally an antioxidant, and optionally a complexing agent, wherein said formulation has a pH of from about 2.0 to about 6.0;
or(b) an alpha adrenergic receptor antagonist, a buffer for maintaining pH, an aqueous solvent, a metal chelator, optionally a tonicity modifier, optionally an antioxidant, and optionally a complexing agent, wherein said formulation has a pH of from about 2.0 to about 6.0, and wherein said stable liquid formulation is present in a dental cartridge or a pre-filled sterile syringe.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.
42 Citations
33 Claims
-
1. A method for increasing blood flow in a mammal comprising administering a stable liquid formulation to said mammal, wherein said stable liquid formulation consists essentially of:
-
(a) a low dose of an alpha adrenergic receptor antagonist, a buffer for maintaining pH, an aqueous solvent, a metal chelator, optionally a tonicity modifier, optionally an antioxidant, and optionally a complexing agent, wherein said formulation has a pH of from about 2.0 to about 6.0;
or(b) an alpha adrenergic receptor antagonist, a buffer for maintaining pH, an aqueous solvent, a metal chelator, optionally a tonicity modifier, optionally an antioxidant, and optionally a complexing agent, wherein said formulation has a pH of from about 2.0 to about 6.0, and wherein said stable liquid formulation is present in a dental cartridge or a pre-filled sterile syringe. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)
-
Specification